Combination Therapy with Fluconazole and Flucytosine for Cryptococcal Meningitis in Ugandan Patients with AIDS
dc.contributor.author | Kizza, Harriet Mayanja | |
dc.contributor.author | Oishi, Kazunori | |
dc.contributor.author | Mitarai, Satoshi | |
dc.contributor.author | Yamashita, Hiroshi | |
dc.contributor.author | Nalongo, Kisembo | |
dc.contributor.author | Watanabe, Kiwao | |
dc.contributor.author | Izumi, Takashi | |
dc.contributor.author | Jungala, Ococi | |
dc.contributor.author | Augustine, Kaddhu | |
dc.contributor.author | Mugerwa, Roy | |
dc.contributor.author | Nagatake, Tsuyoshi | |
dc.contributor.author | Matsumoto, Keizo | |
dc.date.accessioned | 2022-05-20T04:56:55Z | |
dc.date.available | 2022-05-20T04:56:55Z | |
dc.date.issued | 1998 | |
dc.description.abstract | We performed a randomized trial in which combination therapy with fluconazole and shortterm flucytosine was compared with fluconazole monotherapy in 58 patients with AIDS-associated cryptococcal meningitis (CM). Thirty of these patients were randomized to receive combination therapy with fluconazole, 200 mg once a day for 2 months, and flucytosine, 150 mg/(kg·d) for the first 2 weeks, and 28 were randomized to receive monotherapy with fluconazole at the same dose for 2 months. Patients in both groups who survived for 2 months received fluconazole as maintenance therapy at a dose of 200 mg three times per week for 4 months. The combination therapy prevented death within 2 weeks and significantly increased the survival rate among these patients (32%) at 6 months over that among patients receiving monotherapy (12%) (P = .022). The combination therapy also resulted in a significant decrease in the severity of headache after 1 month of treatment, compared with monotherapy (P = .005). No serious adverse reactions were observed in patients receiving either regimen. These data indicate that treatment with fluconazole and short-term flucytosine is a cost-effective and safe regimen that improves the quality of life for patients with AIDSassociated CM in developing countries where human immunodeficiency virus is endemic. | en_US |
dc.identifier.citation | Kizza, H. M., Oishi, K., Mitarai, S., Yamashita, H., Nalongo, K., Watanabe, K., ... & Matsumoto, K. (1998). Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clinical Infectious Diseases, 26(6), 1362-1366.https://doi.org/10.1086/516372 | en_US |
dc.identifier.issn | 1537-6591 | |
dc.identifier.uri | https://nru.uncst.go.ug/handle/123456789/3270 | |
dc.language.iso | en | en_US |
dc.publisher | Clinical Infectious Diseases | en_US |
dc.subject | hiv, acquired immunodeficiency syndrome, cryptococcal meningitis, cost effectiveness, flucytosine, headache, combined modality therapy, developing countries, fluconazole,survival rate, quality of life | en_US |
dc.title | Combination Therapy with Fluconazole and Flucytosine for Cryptococcal Meningitis in Ugandan Patients with AIDS | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 26-6-1362.pdf
- Size:
- 141.72 KB
- Format:
- Adobe Portable Document Format
- Description:
- Combination Therapy with Fluconazole and Flucytosine for Cryptococcal Meningitis in Ugandan Patients with AIDS
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: